Cardio-vascular
Refine Search
Biotechnology
The Institute for Clinical and Economic Review (ICER) has posted its revised Evidence Report assessing the comparative clinical effectiveness of three medicines for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). 6 September 2024
Pharmaceutical
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Pharmaceutical
Lexicon Pharmaceuticals yesterday announced that a post-hoc analysis of Phase III data from the SCORED clinical trial demonstrated that Inpefa (sotagliflozin) reduced the risk of major adverse cardiovascular events. 4 September 2024
Biotechnology
Anthos Therapeutics has reported a new analysis from the landmark AZALEA-TIMI 71 study, demonstrated that the investigational Factor XI inhibitor abelacimab was associated with remarkably low levels of periprocedural bleeding in patients with atrial fibrillation (AFib). 3 September 2024
Pharmaceutical
Germany’s Bayer (BAYN: DE) has presented detailed results from its Phase III OCEANIC-AF trial for the blood thinner asundexian at the annual meeting of the European Society of Cardiology (ESC). 3 September 2024
Pharmaceutical
Novo Nordisk’s semaglutide—marketed under the names Wegovy and Ozempic—have already shown their potential to treat diabetes, obesity, cardiovascular (CV) conditions and maybe even reduce aging, too. 2 September 2024
Pharmaceutical
UK-based George Medicines has announced the presentation of results from its two pivotal Phase III trials at a Hot Line session of the European Society of Cardiology (ESC) Annual Meeting in London. 2 September 2024
Pharmaceutical
Cytokinetics (Nasdaq: CYTK) has presented new data on aficamten, its experimental cardiac myosin inhibitor, at the European Society of Cardiology Congress 2024. 2 September 2024
Generics
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Pharmaceutical
The European subsidiary of Japanese drugmaker Daiichi Sankyo announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. 2 September 2024
Pharmaceutical
Regulatory news last week included European Commission approval for Swiss drugmaker Basilea’s antibacterial Cresemba, triggering a milestone payment from partner Pfizer. On the research front, Neurocrine Biosciences released mixed results from a Phase II study of its NBI-1117568 as a treatment for schizophrenia. Also, Alnylam Pharmaceuticals reported new Phase III data on its vutrisiran in cardiomyopathy. Swiss pharma giant Novartis inked collaboration with Lindy Bioscience aiming to turn biologic drugs into at home injectables, US major Eli Lilly launched a single vial formulation of its fast selling obesity drug Zepbound at a price discount of around 50% compared with other GLP-1 medicines. 1 September 2024
Biotechnology
US RNAi therapeutics company Alnylam Pharmaceuticals today announced what is called positive detailed results from the HELIOS-B Phase III study of vutrisiran, in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). 30 August 2024
Pharmaceutical
Flagship Pioneering yesterday demonstrated further acceleration in its strategic partnership with Pfizer, announcing two research programs with Flagship-founded Quotient Therapeutics. 29 August 2024
Biotechnology
Novartis today announced positive top-line results from twice-yearly Leqvio (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. 28 August 2024
Pharmaceutical
US pharma giant Merck & Co has announced that the European Commission (EC) has approved Winrevair (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with World Health Organization (WHO) functional class (FC) II to III, to improve exercise capacity. 27 August 2024
Biotechnology
BioMarin Pharmaceutical (Nasdaq: BMRN) has announced key leadership changes, appointing Greg Friberg as chief research and development officer, and James Sabry as chief business officer. 21 August 2024
Pharmaceutical
Texas-based Lexicon Pharmaceuticals has announced that, following a strategic review of the company’s commercial and pipeline programs, it will refocus resources across the portfolio and cut jobs. 14 August 2024
Pharmaceutical
Rivus Pharmaceuticals, a clinical-stage drug developer based in Virginia and California, announced that its Phase IIa HuMAIN trial met its primary endpoint of weight reduction. 14 August 2024
Generics
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
Biotechnology
Takeda announced that the European Commission (EC) has approved Adzynma (apadamtase alfa/cinaxadamtase alfa; code name TAK-755) for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP). 8 August 2024
Biotechnology
The Institute for Clinical and Economic Review (ICER) has posted its revised Evidence Report assessing the comparative clinical effectiveness of three medicines for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). 6 September 2024
Pharmaceutical
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Pharmaceutical
Lexicon Pharmaceuticals yesterday announced that a post-hoc analysis of Phase III data from the SCORED clinical trial demonstrated that Inpefa (sotagliflozin) reduced the risk of major adverse cardiovascular events. 4 September 2024
Biotechnology
Anthos Therapeutics has reported a new analysis from the landmark AZALEA-TIMI 71 study, demonstrated that the investigational Factor XI inhibitor abelacimab was associated with remarkably low levels of periprocedural bleeding in patients with atrial fibrillation (AFib). 3 September 2024
Pharmaceutical
Germany’s Bayer (BAYN: DE) has presented detailed results from its Phase III OCEANIC-AF trial for the blood thinner asundexian at the annual meeting of the European Society of Cardiology (ESC). 3 September 2024
Pharmaceutical
Novo Nordisk’s semaglutide—marketed under the names Wegovy and Ozempic—have already shown their potential to treat diabetes, obesity, cardiovascular (CV) conditions and maybe even reduce aging, too. 2 September 2024
Pharmaceutical
UK-based George Medicines has announced the presentation of results from its two pivotal Phase III trials at a Hot Line session of the European Society of Cardiology (ESC) Annual Meeting in London. 2 September 2024
Pharmaceutical
Cytokinetics (Nasdaq: CYTK) has presented new data on aficamten, its experimental cardiac myosin inhibitor, at the European Society of Cardiology Congress 2024. 2 September 2024
Generics
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Pharmaceutical
The European subsidiary of Japanese drugmaker Daiichi Sankyo announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. 2 September 2024
Pharmaceutical
Regulatory news last week included European Commission approval for Swiss drugmaker Basilea’s antibacterial Cresemba, triggering a milestone payment from partner Pfizer. On the research front, Neurocrine Biosciences released mixed results from a Phase II study of its NBI-1117568 as a treatment for schizophrenia. Also, Alnylam Pharmaceuticals reported new Phase III data on its vutrisiran in cardiomyopathy. Swiss pharma giant Novartis inked collaboration with Lindy Bioscience aiming to turn biologic drugs into at home injectables, US major Eli Lilly launched a single vial formulation of its fast selling obesity drug Zepbound at a price discount of around 50% compared with other GLP-1 medicines. 1 September 2024
Biotechnology
US RNAi therapeutics company Alnylam Pharmaceuticals today announced what is called positive detailed results from the HELIOS-B Phase III study of vutrisiran, in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). 30 August 2024
Pharmaceutical
Flagship Pioneering yesterday demonstrated further acceleration in its strategic partnership with Pfizer, announcing two research programs with Flagship-founded Quotient Therapeutics. 29 August 2024
Biotechnology
Novartis today announced positive top-line results from twice-yearly Leqvio (inclisiran) in the Phase III V-MONO study, which met its primary endpoints. 28 August 2024
Pharmaceutical
US pharma giant Merck & Co has announced that the European Commission (EC) has approved Winrevair (sotatercept), in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with World Health Organization (WHO) functional class (FC) II to III, to improve exercise capacity. 27 August 2024
Biotechnology
BioMarin Pharmaceutical (Nasdaq: BMRN) has announced key leadership changes, appointing Greg Friberg as chief research and development officer, and James Sabry as chief business officer. 21 August 2024
Pharmaceutical
Texas-based Lexicon Pharmaceuticals has announced that, following a strategic review of the company’s commercial and pipeline programs, it will refocus resources across the portfolio and cut jobs. 14 August 2024
Pharmaceutical
Rivus Pharmaceuticals, a clinical-stage drug developer based in Virginia and California, announced that its Phase IIa HuMAIN trial met its primary endpoint of weight reduction. 14 August 2024
Generics
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
Biotechnology
Takeda announced that the European Commission (EC) has approved Adzynma (apadamtase alfa/cinaxadamtase alfa; code name TAK-755) for the treatment of ADAMTS13 deficiency in children and adult patients with congenital thrombotic thrombocytopenic purpura (cTTP). 8 August 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze